What is Eligo Bioscience?
Eligo Bioscience operates at the intersection of synthetic biology and microbiome therapeutics. The company specializes in the development of advanced in vivo gene editing tools that allow for the precise modification of bacterial gene repertoires. By targeting the microbiome, Eligo aims to treat complex diseases that have historically proven resistant to traditional pharmacological interventions. This innovative approach, supported by a team of world-class scientists, places the company at the forefront of the next generation of genetic medicine, effectively bridging the gap between foundational research and scalable therapeutic applications.
How much funding has Eligo Bioscience raised?
Eligo Bioscience has raised a total of $55M across 3 funding rounds:
Series A
$20M
Series B
$30M
Grant
$5M
Series A (2017): $20M with participation from Seventure Partners and Khosla Ventures
Series B (2023): $30M led by Bpifrance, Sanofi Ventures, Seventure Partners, and Khosla Ventures
Grant (2025): $5M supported by Ministry for Europe and Foreign Affairs
Key Investors in Eligo Bioscience
Seventure Partners
Seventure Partners is an active partner of innovative companies in the fields of digital technologies and life sciences, focusing on health, nutrition, and sustainable biotechnologies.
Khosla Ventures
Khosla Ventures provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies, with a strong focus on health, AI, and sustainable energy.
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies with transformative potential in immunology and rare diseases.
What's next for Eligo Bioscience?
With the recent influx of capital, Eligo Bioscience is well-positioned to accelerate its research and development pipeline, focusing on the transition from preclinical models to human clinical trials. The strategic focus will likely involve scaling the GEM platform to address a broader spectrum of bacterial-associated pathologies. As the company matures, the emphasis will shift toward establishing robust manufacturing processes and navigating the complex regulatory landscape for gene-editing therapies. Continued collaboration with its diverse investor base will be instrumental in navigating the challenges of commercializing such a disruptive technology, ensuring that Eligo remains a pivotal player in the global biotech ecosystem.
See full Eligo Bioscience company page
